Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine by Mark, D. et al.
Journal Articles 
2019 
Local Radiation Therapy for Palliation in Patients With Multiple 
Myeloma of the Spine 
D. Mark 
P. Gilbo 
R. Meshrekey 
M. Ghaly 
Zucker School of Medicine at Hofstra/Northwell, mghaly@northwell.edu 
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles 
 Part of the Radiation Medicine Commons 
Recommended Citation 
Mark D, Gilbo P, Meshrekey R, Ghaly M. Local Radiation Therapy for Palliation in Patients With Multiple 
Myeloma of the Spine. . 2019 Jan 01; 9():Article 5850 [ p.]. Available from: 
https://academicworks.medicine.hofstra.edu/articles/5850. Free full text article. 
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic 
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara 
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu. 
ORIGINAL RESEARCH
published: 03 July 2019
doi: 10.3389/fonc.2019.00601
Frontiers in Oncology | www.frontiersin.org 1 July 2019 | Volume 9 | Article 601
Edited by:
Timothy James Kinsella,
Warren Alpert Medical School of
Brown University, United States
Reviewed by:
Sonali Rudra,
MedStar Georgetown University
Hospital, United States
Joshua Silverman,
New York University, United States
*Correspondence:
Maged Ghaly
mghaly@northwell.edu
Specialty section:
This article was submitted to
Radiation Oncology,
a section of the journal
Frontiers in Oncology
Received: 11 February 2019
Accepted: 18 June 2019
Published: 03 July 2019
Citation:
Mark D, Gilbo P, Meshrekey R and
Ghaly M (2019) Local Radiation
Therapy for Palliation in Patients With
Multiple Myeloma of the Spine.
Front. Oncol. 9:601.
doi: 10.3389/fonc.2019.00601
Local Radiation Therapy for
Palliation in Patients With Multiple
Myeloma of the Spine
Daniel Mark 1, Philip Gilbo 1, Raymond Meshrekey 2 and Maged Ghaly 1*
1Department of Radiation Medicine, Northwell Health, Lake Success, NY, United States, 2New York Institute of Technology
College of Osteopathic Medicine, Glen Head, NY, United States
Purpose: The objective of this study was to assess a contemporary cohort of patients
with multiple myeloma referred for palliative radiation to the mobile spine for clinical and
radiological responses.
Materials/Methods: The records of patients treated between 2009 and 2016
with radiotherapy for multiple myeloma of the spine were retrospectively reviewed.
Demographics, systemic therapy, radiation dose, number of fractions, radiographic
response based upon adapted RECIST criteria, and symptomatic response
were recorded.
Results: Eighty eight patients and 98 treatment courses were analyzed. All courses were
analyzed for symptomatic response and 61 of the treatment courses were available for
radiologic follow-up. The median follow-up was 9.7 months with a median radiation dose
of 25Gy (12.5–50Gy) delivered in a median of 10 fractions (5–25 fractions). Fifty-four
percent of patients had a high-risk lesion. Symptomatic response as measured by a
decrease of ≤5 points on the pain related scale was 83% and 34% of patients had
a decrease of >5 points. Of 35% of patients that had neurologic impairments prior to
treatment, improvement was identified 83% of the time. Radiographic response was
noted as 13% complete response, 16% partial response, 57% stable disease, and
13% disease progression. Specifically, high-risk lesions treated with radiation alone
demonstrated no regression with only 10% demonstrating partial response.
Conclusion: This retrospective series of patients treated with palliative intent for multiple
myeloma using various dose and fractionation schemes showed favorable symptomatic
relief in most patients. Radiographic response did not correlate with clinical response
with fewer patients having radiologic disease regression. Longer follow-up is necessary
to determine if the lack of radiologic response is associated with clinically relevant
recurrent pain.
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INTRODUCTION
Multiple myeloma is a relatively rare malignancy, with ∼30,770
cases diagnosed per year and 12,770 deaths per year in the
United States as of 2018 (1). It is a neoplasm arising from
plasma cells, post-germinal B cells, which progresses to end-
organ damage, usually involving the bone marrow and involving
the bone in 80% of cases (2, 3). Given its systemic nature,
chemotherapy is the main treatment modality. However, as the
disease involves the bonemarrow/bone, lesionsmay progress and
cause bone pain, fractures, spinal cord/nerve compression, and
may be associated with soft-tissue masses posing a higher risk
to patients. These local lesions require more local therapy such
as surgical excision and/or radiotherapy for symptomatic relief
and/or to prevent further local progression (4). Lesions in the
mobile spine are of particular concern given the proximity to
the spinal cord/cauda equina. The mobile spine is fundamental
to mobility and progression of lesion(s) can lead to a significant
deterioration of quality of life (5). Previous retrospective studies
have noted that local pain control was positively related to applied
radiation dose (6) and others have analyzed surgery on spinal
multiple myelomatous lesions noting that patients undergoing
surgery experienced pain relief as well (7, 8).
In this study we sought to analyze our institutional
experience with treatment of multiple myeloma of the mobile
spine with radiotherapy to assess both radiological and
symptomatic outcomes.
MATERIALS AND METHODS
Patient Inclusion
We retrospectively reviewed the medical records of patients who
were treated for pathologically confirmed multiple myeloma of
the spine treated with palliative intent conventional radiotherapy
between 2009 and 2016 within our multi-center institution. The
study was approved by our institutional review board.
Data Recording
We recorded demographic data including age and sex,
information regarding the patients’ spinal myelomatous
lesion(s), neurological symptomatology before and after
treatment, systemic therapy use, details regarding radiation
including dose, fractionation, duration and modality, including
potential incidences of re-irradiation and recorded radiographic
response based on available imaging and clinical response based
on patient reported pain scores. High-risk lesions were defined
as those with compression fracture(s), cord compression, or
having a paraspinal soft tissue mass component.
We excluded patients who received a single fraction
of radiotherapy and stereotactic body radiation therapy.
We separately assessed patients’ radiological response
assessment from that cohort with documented radiographic
imaging available.
Data Interpretation
Weutilized themost detailed form of imaging and the latest/most
recent imaging to assess one of the primary endpoints of
radiographic response—MRI if available, followed by CT or
PET and X-ray or bone scan if other studies were unavailable
given that the latter studies may show less response due to
delayed time in bone healing compared to PET/CT or MRI.
We determined radiographic response based on adapted RECIST
criteria. Possible response included complete response (no lesion
visible), partial response (improvement of diffuse infiltration or
reduction in size of the focal lesion), stable disease, or progression
(aggravation of the diffuse bonemarrow infiltration or increase in
size of the focal lesion) (9).
In terms of symptomatic response, we utilized a 0–10 numeric
pain rating scale (NPRS) and defined some pain relief as less than
or equal to a decrease of 5 and significant pain relief as greater
than a decrease of 5 on the NPRS. This score was recorded from
the last known follow-up for the patient.
Treatment dose and fractionation was noted andwe compared
doses for radiographic response categories utilizing a one-way
ANOVA test and symptomatic responses utilizing a two-sample,
two-tailed t-test.
RESULTS
Patient Characteristics
Patient and treatment characteristics are summarized in Table 1.
A total of 88 patients and 98 vertebral segments treated with
palliative radiotherapy were retrospectively reviewed. Of the 98
treatment courses, 61 (62%) had appropriate follow-up imaging
to assess radiological response. Median follow-up for these
patients, defined as time from date of last fraction of radiotherapy
to time of latest radiological exam was 9.7 months (0.1–107.5
months). Thirty three of the 61 treatment-courses were for
high-risk lesions including 8 treatments for cord compression,
19 treatments for compression fractures, and 6 treatments for
lesions with a paraspinal soft tissue mass component.
The median number of fractions administered was 10 (mean
9.8, range 5–25), and median radiation dose administered was
25 (mean 27.1Gy, range 12.5–50Gy). The three most common
TABLE 1 | Patient characteristics.
Patient Characteristics N (%) or [range]
Number of patients 88
Male
Female
46 (52%)
42 (48%)
Median age 65 [43–98]
Number of vertebral segments treated 98
Known systemic therapy administration 83 (94%)
Number of sites with radiographic follow-up 61 (62%)
Median number of radiotherapy fractions 10 [5–25]
Median radiologic follow-up 9.7 months [0.1–107.5
months]
High-risk features 33 of 61 (54%)
Cord compression
Compression fractures
Paraspinal soft tissue component
8
19
6
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TABLE 2 | Radiological response.
Response characteristics N (%)
Adapted RECIST criteria radiological response (n = 61)
Complete response
Partial response
Stable disease
Progression
8 (13%)
10 (16%)
35 (57%)
8 (13%)
Patients with high-risk features (n = 33)
Radiotherapy alone
Complete response
Partial response
Stable disease
Progression
Surgery+RT* with complete/partial response
0 (0%)
3 (9%)
25 (76%)
2 (6%)
3 (9%)
Patients without high-risk features (n = 28)
Radiotherapy alone
Complete response
Partial response
Stable disease
Progression
Surgery+RT* with complete/partial response
4 (14%)
5 (18%)
10 (36%)
6 (21%)
3 (11%)
*RT, radiation therapy.
fractionation schemes were 30Gy in 10 fractions (n= 16), 20Gy
in 5 fractions (n= 13), and 24Gy in 8 fractions (n= 10).
Systemic therapy was documented in 83 of the 88 patients
(94%) and included chemotherapy, steroids, and/or stem cell
transplant within several weeks their radiotherapy course. For
5 patients, chemotherapy was either refused or no records
were available.
Radiological Response
Table 2 summarizes radiological treatment responses in all
patients and also stratifies those with and without high-
risk features.
Of the 61 treatment courses with radiological follow-up,
it is noted that 8 (13%) experienced complete response, 10
(16%) experienced partial response, 35 (57%) experienced stable
disease, and 8 (13%) experienced local progression.
We further stratified the data by patients who had high-
risk features as defined previously. Thirty three (54%) of the
treatment courses were for patients with high-risk feature
types. Surgery was performed on 3 of these lesions prior to
radiation therapy, and these patients achieved a local partial or
complete response. The remaining 30 vertebral segments were
treated with radiation therapy without surgical excision. None of
these patients achieved complete response to radiation therapy
alone, 3 lesions (10%) demonstrated partial response, 25 lesions
(83%) demonstrated stability, and 2 lesions (7%) demonstrated
progression as demonstrated in Figure 1.
The remaining 28 patients were without high-risk features.
Surgery was performed on 3 of these lesions as well, with all
achieving a local partial or complete response. Of the remaining
25 lesions, 4 lesions (16%) demonstrated complete response, 5
lesions (20%) demonstrated partial response, 10 lesions (40%)
FIGURE 1 | Sites with high-risk features treated with radiation alone.
FIGURE 2 | Sites without high-risk features treated with radiation alone.
TABLE 3 | Pain response.
Response characteristics N (%)
Pain relief from radiation therapy (n = 98)
Some degree (pain score decrease ≤ 5)
Significant (pain score decrease > 5)
81 (83%)
33 (34%)
demonstrated stable disease, and 6 lesions (24%) demonstrated
progression as demonstrated in Figure 2.
Symptomatic Response
Table 3 summarizes symptomatic relief from radiotherapy,
including those without radiological follow-up.
Patients experienced some degree of pain relief after
radiotherapy 83% of the time, and had significant relief of pain
34% of the time.
Patients had neurological impairments such as impaired
ability to walk, paresthesias, and extremity weakness in 34 of 98
treatments and this was improved with palliative radiotherapy
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TABLE 4 | Radiological/symptomatic response and dose levels.
Response characteristics Mean dose
[Range]
p-value
Radiological response (n = 61) p = 0.74 (ns)
Complete response
Partial response
Stable disease
Progression
27.2Gy [20–39.6]
29.6Gy [20–50]
26.9Gy [12.5–50]
25.3Gy [20–30]
Pain relief from radiation therapy (n = 98) p = 0.20 (ns)
Some degree (pain score decrease > 1, ≤ 5)
Significant (pain score decrease > 5)
24.0Gy [16–50]
26.0Gy [18–50]
in 28 of the treatments (83%). Specifically, impaired ability
to walk was noted prior to 25 of the 98 treatments and
this was improved with palliative radiotherapy in 19 of the
treatments (76%).
Additional Analyses of Dose
and Relationships
Table 4 summarizes the relationship between radiation dose
and radiographic/clinical responses. There was not a statistically
significant difference between mean doses administered between
the groupings (p= 0.74 on a one-way ANOVA).
No dose response was noted for the clinical response of all
patients (p= 0.20 on a two-sample, two-tailed t-test).
DISCUSSION
This is a contemporary cohort study of patients undergoing
palliative radiotherapy to the mobile spine using conventional
radiation techniques to various doses and using various
fractionation schemes in patients undergoing systemic
therapy. We were able to identify good clinical symptom
relief in the majority of patients but failed to correlate that
to radiographic responses, in particular to those patients
with high-risk features. The radiographic response was
10% in patients with high-risk features who received
radiation alone, despite the wide variety of radiation
doses and schemes employed. Most patients experienced
some form of pain response, with a subset experiencing
a significant pain response. Further, many patients with
neurological deficits, including impairment of the ability to
walk, were palliated with radiotherapy, including many with
high-risk features.
These results question whether a radiographic response
is required when treating Multiple myeloma patients with
or without high-risk features. In plasmacytoma, it has been
demonstrated that doses 45Gy and higher (10) are needed to
achieve a sufficient response and in multiple myeloma for cord
compression longer course radiotherapy has been suggested and
associated with better functional outcomes than short course RT
(11). Nevertheless, in high-risk lesions or in those for whom
a significant mass reduction would be considered desirable,
we were able to demonstrate symptomatic relief. Therefore, is
an increased dose or alternative fractionation schedules such
as stereotactic body radiation therapy (SBRT) necessary? As
compared to some of these older studies, the majority of
our patients also received systemic therapies that may also be
contributing to symptomatic relief.
Weakness of this study include the inherent biases associated
with retrospective reviews and incomplete long-term follow-up.
In addition, there was no consistent radiation dose, fractionation
scheme or field size criteria used in this cohort. Lastly, given the
discordance between symptom relief and radiographic response,
longer and more comprehensive follow-up is needed in this
patient population to determine if radiologic response is a good
surrogate for measuring outcomes.
Others have explored the use of SBRT for patients with good
performance status in a similar patient cohort with promising
results (12–14). While fewer fractions may be desirable in a
palliative setting, the use of SBRT nonetheless requires further
study at least until the best desirable endpoint measure is known.
In summary, this retrospective review of patients who
received palliative radiotherapy with a varying degree of doses
and fractionation demonstrated good symptomatic response
relief but variable radiological response. Patients with high-
risk lesions demonstrated less of a radiological response
with conventional radiotherapy alone. Further follow up is
necessary to identify the best measurable outcome as a means
of determining if radiologic response is key to long term
symptom relief.
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